Does Aetna Medicare Cover Wegovy for Weight Loss?

Aetna Medicare plans do not cover Wegovy when it is prescribed for weight loss. The restriction is not Aetna’s call: Medicare Part D has been barred by statute from covering weight loss drugs since the benefit was created in 2003, and that applies to every Part D plan and every Medicare Advantage plan with drug coverage.¹ A new federal demonstration beginning July 1, 2026 will give many Medicare beneficiaries access to Wegovy for $50 a month outside the Part D benefit, no matter which plan they are enrolled in.²

Why the Answer Is No

Congress wrote the weight loss drug exclusion into Part D when it created the prescription benefit, and that language is still on the books.³ Every Part D plan, including Aetna’s standalone drug plans and the drug coverage inside Aetna Medicare Advantage, is prohibited from paying for GLP-1 medications such as Wegovy or Zepbound when the prescription is for weight management.⁴

CMS proposed a regulatory change in late 2024 that would have reinterpreted the exclusion and allowed coverage. The agency announced in April 2025 that it would not finalize that proposal, leaving the statutory bar in place.⁵

The $50 Monthly Workaround Starting July 2026

Because the law has not changed, CMS is using its demonstration authority to open a separate lane. The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and lets eligible Part D beneficiaries get Wegovy, Zepbound (KwikPen), or Foundayo for a flat $50 monthly copay.⁶⁷ Wegovy is covered in both the injection and oral tablet forms.

The Bridge runs outside the Part D benefit entirely. A central processor designated by CMS handles prior authorization, claims, and pharmacy payment, so Aetna is not involved in approving or paying for the prescription even if you are an Aetna member.⁶

Who Qualifies

You need to be enrolled in a Medicare Part D plan (standalone or through Medicare Advantage), be at least 18, and have the drug prescribed for weight management. You also have to meet one of these clinical thresholds at the time treatment started:⁸

BMI of 35 or higher, with no additional diagnosis required.
BMI of 30 or higher, with a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease (stage 3a or above).
BMI of 27 or higher, with a diagnosis of pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.

How To Get a Prescription Filled

You don’t enroll in the Bridge separately. Your doctor submits the prior authorization request and prescription to the CMS-designated central processor rather than to Aetna, and the pharmacy then bills claims electronically using a BIN/PCN number specific to the program.⁸⁶

What the $50 Does and Does Not Do

You pay $50 for each monthly supply. Participating manufacturers provide the drug at a net price of $245 a month, and the central processor pays the pharmacy the balance plus a dispensing fee.⁷

One thing to know up front: the $50 does not count toward your Part D deductible or your annual Part D out-of-pocket cap, and Extra Help (the Low-Income Subsidy) does not reduce it. The Bridge sits in its own financial lane, parallel to the standard Part D benefit.¹

When Aetna Medicare Can Pay for Wegovy

Wegovy has a second FDA-approved use that is not weight loss. In March 2024, the FDA approved it for reducing the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with established heart disease who also have obesity or are overweight.⁹ That approval came from the SELECT trial, which reported a 20% relative risk reduction in major cardiovascular events across more than 17,000 participants.¹⁰

Prescribed for cardiovascular risk reduction instead of weight loss, Wegovy can be covered under a standard Part D plan, including Aetna Medicare plans.⁴ Aetna reportedly began covering Wegovy for Medicare Advantage members for the cardiovascular indication after federal regulators authorized traditional Medicare coverage for heart disease patients.¹¹ When Wegovy is covered this way, what you spend counts toward the annual Part D out-of-pocket cap.

If Wegovy is not on your Aetna Medicare formulary for this use, you or your prescriber can request a formulary exception through the member portal or by calling the number on your ID card.¹² CMS rules give the plan 72 hours to decide a standard exception, or 24 hours for an expedited one, as long as the prescriber provides a supporting statement explaining medical necessity.¹³

What Happens After 2027

The Bridge was built as a stopgap for a longer-term program called the BALANCE Model, which would have let Part D sponsors cover GLP-1 drugs for obesity starting January 1, 2027. The Medicare side of BALANCE needed 80% of Part D sponsors (by enrollment) to sign on. That threshold was not met. CVS Health, which owns Aetna, said it would not participate, and UnitedHealthcare also declined.¹⁴ CMS has paused BALANCE in Part D indefinitely and extended the Bridge through December 31, 2027.⁸

What follows 2027 is open. Without new legislation or another demonstration, Medicare members would again lose weight-loss access to these drugs when the Bridge ends.

If Nothing Applies, What Wegovy Costs

If you don’t qualify for the Bridge and your prescription isn’t for the cardiovascular indication, a monthly supply of Wegovy runs about $1,350 without insurance.⁴

Starting January 1, 2027, the Medicare Drug Price Negotiation Program takes effect for the semaglutide product group, which includes Wegovy. CMS set a Maximum Fair Price of roughly $274 for the group, with the 2.4 mg Wegovy injection pen priced at $385.63 for a four-pen supply.¹⁵ Those negotiated prices only apply when the drug is actually covered under Part D, so they would help someone getting Wegovy for the cardiovascular indication, not someone paying cash for weight loss.

Novo Nordisk’s patient assistance program, NovoCare, stopped supporting Medicare beneficiaries who have prescription drug coverage as of 2026. The company now points Medicare patients to Extra Help and the Medicare Prescription Payment Plan, which spreads prescription costs into monthly installments across the year.¹⁶¹⁷

1
Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
2
CMS. CMS To Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
3
National Library of Medicine. Medicare Coverage of Anti-Obesity Medications
4
Aetna. Does Medicare Cover Ozempic
5
Healio. CMS Decision To Remove Obesity Drug Coverage From 2026 Final Rule Disappoints Societies
6
CMS. Medicare GLP-1 Bridge
7
CMS. Medicare GLP-1 Bridge – Information for Part D Plans
8
CMS. Medicare GLP-1 Bridge – Information for Providers
9
FDA. Wegovy Prescribing Information
10
Novo Nordisk. Wegovy – Reduce MACE Risk
11
Modern Healthcare. Kaiser, Aetna Wegovy Medicare Advantage
12
Aetna. Drug Information Resources
13
CMS. Part D Exceptions
14
Becker’s Payer Issues. CMS Pauses Weight Loss BALANCE Model Indefinitely for Medicare
15
AMCP. CMS Releases IPAY 2027 Negotiated Prices
16
MCT2D. NovoCare Discontinues Assistance Program for Medicare Patients in Need
17
Novo Nordisk. Navigating Medicare